Research: Investigate GLP-1 Impact on Functional Soda Transition

Investigating GLP-1 Impact on Functional Soda and Beverage Transition

The widespread adoption of GLP-1 receptor agonists (such as Ozempic, Wegovy, and Mounjaro) is fundamentally reshaping the global food and beverage landscape. With an estimated 18% of U.S. adults reporting past or present use of these medications [15], the traditional beverage market faces a projected $48 billion reduction in annual consumer spending over the next decade due to reduced caloric intake and suppressed appetites [4].

However, while traditional categories face headwinds, the market for functional beverages—particularly those addressing the specific nutritional and gastrointestinal needs of GLP-1 users—is experiencing a significant boom [2, 3]. Beverage companies are increasingly relying on functional-premiumization and a multi-beverage-strategy to capture evolving consumption occasions.

The Functional Beverage and Soda Boom

The physiological effects of GLP-1 medications include delayed gastric emptying and early satiety, which inherently shift consumer preference toward beverages that offer high nutrient density in small volumes [1, 8].

Prebiotic and Probiotic Sodas

GLP-1 treatments frequently cause gastrointestinal side effects, including nausea, bloating, constipation, and in severe cases, Small Intestinal Bacterial Overgrowth (SIBO) due to slowed digestion [8, 10, 15]. Consequently, users are strongly advised to incorporate dietary fiber, prebiotics, and probiotics to support gut microbiome health and mitigate side effects [7, 10].

This medical necessity is accelerating a transition away from traditional sodas toward functional sodas. Clinical research organizations are actively studying whether prebiotic sodas can directly reduce stomach discomfort for GLP-1 users [9]. The shift provides a massive tailwind for prebiotic soda brands like olipop and poppi (recently acquired by pepsico), which mainstream the delivery of gut-health benefits in a familiar carbonated format [9].

Protein and Hydration Beverages

Due to the risk of significant lean muscle mass loss associated with rapid weight reduction (nearly 40% of weight loss on GLP-1s can be lean mass without proper nutrition), high-protein functional beverages have become the most widely consumed product type among users [2, 3]. In 2025, high-protein beverages commanded a 31.4% share of the GLP-1 food and beverage market, equivalent to approximately $1.44 billion [1]. Similarly, the category has seen accelerated growth in hydration and electrolyte drinks to combat medication-induced dehydration and nausea [3].

Disruption of Traditional Beverage Categories

Carbonated Soft Drinks (CSD) and Diet Sodas

Traditional carbonated-soft-drinks-csd are among the most heavily disrupted beverage categories [2]. Notably, even diet and zero-calorie sodas are facing scrutiny from GLP-1 users. While diet sodas are low in calories, medical professionals note they provide no nutritional benefits to patients who must hyper-focus on nutrient density due to suppressed appetites [3, 6]. Furthermore, studies suggest that artificial sweeteners common in diet sodas, such as sucralose and aspartame, may increase insulin resistance and stimulate appetite, directly counteracting the metabolic goals of GLP-1 therapy [6, 8].

Impact on Alcohol Consumption

The glp-1-impact-on-alcohol-consumption is profound, as these medications alter the brain’s reward pathways, naturally reducing cravings for alcohol [5, 13]. Clinical studies indicate that participants taking semaglutide report drinking 30% to 50% fewer alcoholic beverages per week [14].

Rather than complete abstention, this has led to a widespread adoption of damp-drinking and intentional moderation. Data shows that 44% of users drink less after starting GLP-1s, and 82% maintain these reduced habits even after stopping treatment [12]. This behavioral shift signifies the “death knell of the volume growth model” for the mainstream alcohol industry, forcing brands to pivot toward premiumization and high-quality, lower-volume adult-soft-drinks to maintain profitability [3, 11]. Wine has been disproportionately affected, showing a 52% decline in consumption among users who cut back, compared to 43% for beer [12].

Strategic Responses and Share of Occasion

As traditional volume metrics decline, beverage companies are pivoting to capture a new share-of-occasion.

• Focus on Satiety and Clean Labels: Users favor beverages offering blood sugar balance, satiety, and calorie transparency, particularly in solitary or at-home occasions [3, 12].
• Low/No Alcohol Expansion: The low/no alcohol segment is projected to grow at a 13.6% CAGR (2024–29) in the US, acting as a buffer against the cannibalization of traditional alcohol sales [12].

Contradictions and Research Gaps

• Alcohol Abstinence vs. Moderation: While some reports emphasize a total loss of desire to drink among GLP-1 users [14], broader consumer data reveals that users still over-index as high-category buyers of alcohol; their consumption is simply more selective and lower in volume [11].
• Medical Guidelines on Alcohol Integration: There is currently a significant gap in long-term clinical studies and official medical guidelines regarding safe limits for mixing alcohol with GLP-1 medications, leaving patients to rely on anecdotal evidence and generalized caution [13].
• Artificial Sweeteners: The exact metabolic effect of artificial sweeteners (used in diet sodas) on GLP-1 efficacy remains clinically unclear, though observational data warns against their use [6].

Suggested Additional Sources

To further expand this wiki page, researchers should investigate:

1. Sales velocity data isolating cross-purchasing trends between GLP-1 prescriptions and specific functional soda brands (e.g., scanner data from Circana or NielsenIQ).
2. FDA or clinical literature specifically evaluating the efficacy of beverage-format prebiotics in treating semaglutide-induced gastroparesis.
3. Sell-side analyst reports detailing how major beverage conglomerates (e.g., Coca-Cola, Keurig Dr Pepper) are reformulating product portfolios to align with the “GLP-1 diet.”

References

1. GLP-1 Drug Impact on Food & Beverage Consumer Market Research Report 2034 — marketintelo.com
2. GLP-1 drugs stir change in the beverage industry - AlixPartners — alixpartners.com
3. Five ways GLP-1 drugs are affecting the beverage industry — beveragedaily.com
4. [PDF] Getting to know GLP-1 users, a new kind of consumer — kpmg.com
5. How GLP-1 Medications Are Reshaping Consumer Behavior - Holmes Murphy — holmesmurphy.com
6. Ozempic Diet Plan: A List of Foods to Eat and What to Avoid — healthline.com
7. Why Gut Health Matters When Taking Ozempic – AmBari Nutrition — ambarinutrition.com
8. 5 Ozempic Foods to Avoid and What to Eat Instead, Per Doctors — prevention.com
9. Prebiotic Soda GI Symptoms Support Study for GLP-1 Users — studies.peoplescience.health
10. Gastroparesis and Ozempic: Understanding Stomach Paralysis | Dr Hagmeyer — drhagmeyer.com
11. Exploring GLP-1 Users’ Relationship with Alcohol and THC Drinks — morningconsult.com
12. GLP-1 shifts alcohol market dynamics | EY - US — ey.com
13. GLP-1 Drugs Like Ozempic and Alcohol: Potential Issues — webmd.com
14. GLP-1 and Alcohol Cravings: Why Some People Stop Wanting to Drink - Doctronic — doctronic.ai
15. How GLP-1s are changing people’s lives in unexpected ways — cnbc.com